Vientiane, Laos - January 3, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on the development and commercialization of innovative cancer therapies, announced that Trelagliptin has been approved by the Lao Ministry of Health. It will be sold under the brand name TEGLIDX.
Trelagliptin is an ultra-long-acting dipeptidyl peptidase IV (DPP-4) inhibitor that effectively controls blood glucose with just one oral dose per week.
Indication
Trelagliptin is indicated for type 2 diabetes mellitus. This drug should only be considered for use in patients who have already adequately implemented diet and exercise therapy as the foundation of diabetes treatment, but with insufficient results.
Dosage and Administration
1. For adults, take 100 mg orally once weekly.
2. Trelagliptin is a once-weekly medication and should be taken on the same day each week.
3. If a dose of Trelagliptin is missed, take the prescribed dose as soon as noticed, then continue taking it on the pre-scheduled day of the week.
Common Adverse Reactions
Including hypoglycemia, gastrointestinal symptoms, liver function abnormalities, allergic reactions, etc. Some patients may experience serious adverse reactions.
Precautions
1. Due to the risk of hypoglycemia, patients should be fully informed about the symptoms of hypoglycemia and how to respond, and their attention should be drawn to this.
2. Acute pancreatitis may occur. Therefore, if a patient experiences initial symptoms such as persistent severe abdominal pain or vomiting, instruct the patient to seek medical examination as soon as possible.
3. Trelagliptin is a once-weekly oral medication, and its effect persists after discontinuation. Therefore, blood glucose levels and the occurrence of side effects should be carefully monitored. Furthermore, when switching to another antidiabetic drug after discontinuing Trelagliptin, the timing and dosage of initiation should be considered based on blood glucose control status, etc.
4. During administration of Trelagliptin, blood glucose should be checked regularly and disease progression should be carefully observed. If the effect is still insufficient after 2 to 3 months of treatment with Trelagliptin, consider switching to a more appropriate treatment regimen.
5. Because hypoglycemic symptoms may occur, caution should be exercised when administering the drug to patients engaged in working at heights, driving a car, etc.
6. Both Trelagliptin and GLP-1 receptor agonists exert glucose-lowering effects through the GLP-1 receptor. There are currently no clinical trial results on the combination of these two drugs, and its efficacy and safety have not been established.
